At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PROK ProKidney Corp.
Pre-Mkt 04-10 06:40:30 EDT
1.90
+0.05
+2.70%
High1.92Low1.84Vol538.50K
Open1.84D1 Closing1.85Amplitude4.59%
Mkt Cap573.64MTradable Cap525.98MTotal Shares301.92M
T/O1.01MT/O Rate0.19%Tradable Shares276.83M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

ProKidney appoints Greg Madison as chief commercial officer
TIPRANKS  ·  03-26
ProKidney appoints Greg Madison as chief commercial officer
BRIEF-Prokidney Expands Senior Leadership Team With Appointment Of Greg Madison As Chief Commercial Officer
Reuters  ·  03-26
BRIEF-Prokidney Expands Senior Leadership Team With Appointment Of Greg Madison As Chief Commercial Officer
Press Release: ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
Dow Jones  ·  03-26
Press Release: ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
Trade Policy Risks: How Evolving U.S. Tariffs and Export Rules Threaten ProKidney Corp.’s Supply Chain and Financial Stability
TIPRANKS  ·  03-20
Trade Policy Risks: How Evolving U.S. Tariffs and Export Rules Threaten ProKidney Corp.’s Supply Chain and Financial Stability
Analysts Offer Insights on Healthcare Companies: ProKidney (PROK), Molecular Partners (MOLN) and Bristol-Myers Squibb (BMY)
TIPRANKS  ·  03-19
Analysts Offer Insights on Healthcare Companies: ProKidney (PROK), Molecular Partners (MOLN) and Bristol-Myers Squibb (BMY)
Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), HeartFlow, Inc. (HTFL) and Arvinas Holding Company (ARVN)
TIPRANKS  ·  03-19
Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), HeartFlow, Inc. (HTFL) and Arvinas Holding Company (ARVN)
Prokidney Corp reports results for the quarter ended December 31 - Earnings Summary
Reuters  ·  03-19
Prokidney Corp reports results for the quarter ended December 31 - Earnings Summary
ProKidney Q4 EPS $(0.14) Misses $(0.11) Estimate, Sales $225.000K Beat $83.333K Estimate
Benzinga  ·  03-19
ProKidney Q4 EPS $(0.14) Misses $(0.11) Estimate, Sales $225.000K Beat $83.333K Estimate
ProKidney reports Q4 EPS (52c), consensus (15c)
TIPRANKS  ·  03-19
ProKidney reports Q4 EPS (52c), consensus (15c)
ProKidney FY2025 revenue rises more than 10x to USD 0.89 million as net loss before noncontrolling interest narrows 7.18% to USD 151.61 million
Reuters  ·  03-19
ProKidney FY2025 revenue rises more than 10x to USD 0.89 million as net loss before noncontrolling interest narrows 7.18% to USD 151.61 million
Press Release: ProKidney Reports Full Year 2025 Financial Results and Business Highlights
Dow Jones  ·  03-19
Press Release: ProKidney Reports Full Year 2025 Financial Results and Business Highlights
Prokidney Corp expected to post a loss of 12 cents a share - Earnings Preview
Reuters  ·  03-11
Prokidney Corp expected to post a loss of 12 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Coca-Cola, Rapid7, Walmart
Reuters  ·  02-11
U.S. RESEARCH ROUNDUP-Coca-Cola, Rapid7, Walmart
ProKidney Corp : Jefferies Assumes Coverage With Buy Rating; Target Price $4.5 VS $6
THOMSON REUTERS  ·  02-11
ProKidney Corp : Jefferies Assumes Coverage With Buy Rating; Target Price $4.5 VS $6
BRIEF-Prokidney Corp - Topline Data Readout Of Surrogate Endpoint Expected Q2 2027
Reuters  ·  02-03
BRIEF-Prokidney Corp - Topline Data Readout Of Surrogate Endpoint Expected Q2 2027
ProKidney Corp - Topline Data Readout of Surrogate Endpoint Expected Q2 2027 - SEC Filing
THOMSON REUTERS  ·  02-03
ProKidney Corp - Topline Data Readout of Surrogate Endpoint Expected Q2 2027 - SEC Filing
ProKidney Corp - Updates Phase 3 Study Enrollment to 470 Subjects - SEC Filing
THOMSON REUTERS  ·  02-03
ProKidney Corp - Updates Phase 3 Study Enrollment to 470 Subjects - SEC Filing
3 Penny Stocks With Market Caps Under $700M
Simply Wall St.  ·  01-08
3 Penny Stocks With Market Caps Under $700M
HC Wainwright Initiates Coverage on ProKidney With Buy Rating, $12 Price Target
MT Newswires Live  ·  2025-12-16
HC Wainwright Initiates Coverage on ProKidney With Buy Rating, $12 Price Target
ProKidney Initiated at Buy by HC Wainwright & Co.
Dow Jones  ·  2025-12-16
ProKidney Initiated at Buy by HC Wainwright & Co.

Introduction

Company Name.
ProKidney Corp.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Issue price:
--